Exactly... on various counts Mesoblast shares a
Post# of 148151
Quote:
Mesoblast shares are trading higher after the company reported 10 out of 12 patients with ventilator-dependent coronavirus infection survived following 2 intravenous infusions of co.'s allogeneic mesenchymal stem cell product candidate Remestemcel-L.
Would be great to hear how Leronlimab stacks up when our human data is out... "10 out of 12" sounds terrific but in any case, the idea should always be to get whatever drug to save lives as expeditiously as possible, hopefully without major side effects.
And if there are two or three or six drugs that can help Covid-19 patients at all or various stages of illness, especially with no major negatives... it's good, as we have a world in need of something... right now.
And regarding their pps, they shot up over 300% near opening this morning... wonder what CYDY will do when our news is out, lol